Real-World Safety of Sacubitril/Valsartan in Women and Men With Heart Failure and Reduced Ejection Fraction: A Meta-analysis

BACKGROUND: Sacubitril/valsartan (SV) is a novel and effective therapy for heart failure with reduced ejection fraction (HFrEF). Despite several sex-specific particularities that may influence drug effects, there has been no prior study evaluating the safety of SV in women with HFrEF in the “real-wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Nuechterlein, Kaitlin, AlTurki, Ahmed, Ni, Jiayi, Martínez-Sellés, Manuel, Martens, Pieter, Russo, Vincenzo, Backelin, Charlotte Nordberg, Huynh, Thao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Systematic Review/Meta-analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712592/
https://www.ncbi.nlm.nih.gov/pubmed/34993450
http://dx.doi.org/10.1016/j.cjco.2021.09.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712592/
https://www.ncbi.nlm.nih.gov/pubmed/34993450
http://dx.doi.org/10.1016/j.cjco.2021.09.009

Ejemplares similares